Multilayered polysaccharide nanofilms for ... - ACS Publications

c University Medical Centre Maribor, Division of Surgery, Department of .... administration) of venous ulceration, where it was found to improve its ...
0 downloads 0 Views 5MB Size
Subscriber access provided by UNIVERSITY OF ADELAIDE LIBRARIES

Article

Multilayered polysaccharide nanofilms for controlled delivery of pentoxifylline and possible treatment of chronic venous ulceration Jan Stana, Janja Stergar, Lidija Gradišnik, Vojko Flis, Rupert Johann Kargl, eleonore froehlich, Karin Stana Kleinschek, Tamilselvan Mohan, and Uros Maver Biomacromolecules, Just Accepted Manuscript • DOI: 10.1021/acs.biomac.7b00523 • Publication Date (Web): 04 Aug 2017 Downloaded from http://pubs.acs.org on August 5, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Biomacromolecules is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Multilayered polysaccharide nanofilms for controlled delivery of pentoxifylline and possible treatment of chronic venous ulceration Jan Stanaa, Janja Stergarb, Lidija Gradišnikb, Vojko Flisc, Rupert Kargld, Eleonore Fröhliche, Karin Stana Kleinschekd, Tamilselvan Mohanf,*, Uroš Maverb,g,* a

Schön Klinik Vogtareuth, Department of Vascular and Endovascular Surgery, Krankenhausstraße 20, 83569 Vogtareuth, Germany b University of Maribor, Faculty of Medicine, Institute of Biomedical Sciences, Taborska ulica 8, SI-2000 Maribor, Slovenia c University Medical Centre Maribor, Division of Surgery, Department of Vascular Surgery, Ljubljanka ulica 5, SI-2000 Maribor, Slovenia d University of Maribor, Faculty of Mechanical Engineering, Laboratory for Characterisation and Processing of Polymers, Smetanova 17, SI-2000 Maribor, Slovenia e University of Graz, Institute of Chemistry, Heinrichstrasse 28, 8010 Graz, Austria f Medical University of Graz, Center for Medical Research, Core Facility Microscopy, Stiftingtalstraße 24, 8010 Graz, Austria g University of Maribor, Faculty of Medicine, Department of Pharmacology, Taborska ulica 8, SI-2000 Maribor, Slovenia

*Corresponding authors Assist. prof. dr. Uroš Maver, head of the Institute of Biomedical Sciences University of Maribor, Faculty of Medicine Institute of Biomedical Sciences Taborska ulica 8, SI-2000 Maribor, Slovenia [email protected] Phone: +386 2 234 5823

Dr. Tamilselvan Mohan University of Graz Institute of Chemistry Heinrichstrasse 28, 8010 Graz, Austria [email protected] Phone: +43 316 380 5413

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ABSTRACT

Local drug delivery systems made from non-toxic polysaccharide nanofilms have an enormous potential in wound care. A detailed understanding of the structural, surface, physicochemical and cytotoxic properties of such systems is crucial to design clinically efficacious materials. Herein, we fabricated polysaccharide-based nanofilms onto either a 2D model (SiO2 and Au-sensors) or on non-woven alginate 3D substrates using an alternating assembly of N,N,N-trimethylchitosan (TMC) and alginic acid (ALG) prepared by a spinassisted layer-by-layer (LbL) technique. These TMC/ALG multi-layered nanofilms are used for a uniform encapsulation and controlled release of pentoxifylline (PTX), a potent antiinflammatory drug for treatment of the chronic venous ulceration. We show a tailorable film growth and mass, morphology, as well as surface properties (charge, hydrophilicity, porosity) of the assembled nanofilms through control of the coating during the spin-assisted assembly. The uniform distribution of the encapsulated PTX in the TMC/ALG nanofilms is preserved even with when the amount of the incorporated PTX increases. The PTX release mechanism from the model and real systems is studied in detail and is very comparable for both systems. Finally, different cell based assays illustrated the potential of the TMC/ALG multilayer system in wound care (e.g., treatment chronic venous ulceration) applications, including a decrease of TNF-α secretion, a common indicator of inflammation.

Keywords: Trimethylchitosan, alginate, pentoxifylline, chronic venous ulceration, multilayered films, wound dressings

ACS Paragon Plus Environment

Page 2 of 58

Page 3 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

1

1

2

Wound healing generally follows a well-defined yet complex cascade of processes commonly

3

divided into four main stages; coagulation, inflammation, cell proliferation with repair of the

4

matrix and epithelialization with remodeling of the scarred tissue1. Wounds are often

5

classified as being either acute or chronic. In general, acute wounds are healed within an

6

expected time frame, and if not, they in essence become chronic wounds. Wounds labeled

7

“chronic” are often merely symptoms of other long-standing or overwhelming problems2, 3.

8

The venous ulceration is a common chronic wound type that presents a major socio-economic

9

problem in the western society. In Europe 5% of the population suffers from chronic venous

10

insufficiency, from which 1% develops chronic venous ulceration4. Histopathological and

11

immunological findings have shown that chronic inflammation plays a pivotal role in the

12

development of venous ulcerations5, 6. One of the possible hypotheses for the up-regulation of

13

leukocyte activation that accompanies the chronic inflammation, could be in the rheological

14

changes due to chronic venous insufficiency 7. Namely, the changed sheer stress on the

15

endothelium of the vascular wall is responsible for the higher expression of ICAM-1

16

(intracellular adhesion molecule 1), VCAM-1 (vascular intracellular adhesion molecule 1),

17

PECAM-1 (platelet endothelial cell adhesion molecule 1), as well as E-, L-selectins, which

18

contribute to an increased leucopedesis 6. In the next step the activation of the leukocytes,

19

especially neutrophils and macrophages, takes place. This results in a higher concentration of

20

their products (e.g., leukotrienes, free oxygen radicals and cytokines IL-1 (interleukin 1), IL-6

21

(interleukin 6) and TNF-α (tumour necrosis factor)) in the wound fluid of chronic venous

22

ulceration

23

non-healing wounds, demonstrating its importance in chronic wound care 11, 12.

24

Considering the mentioned, our study focused on the controlled release of pentoxifylline

25

(PTX), an already clinically proven effective drug in the systemic treatment (oral

INTRODUCTION

8-10

. TNF-α is found in much higher concentrations in the wound fluid of chronic

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

26

administration) of venous ulceration, where it was found to improve its healing rate 13, 14. PTX

27

is a xanthine derivative, whose anti-inflammatory action can be related to a non-selective

28

phosphodiesterase inhibition, raising intracellular cAMP (cyclic adenosine monophosphate)

29

concentrations, inhibition of TNF-α and leukotriene synthesis, as well as the initiation of

30

immunity 15, 16. Namely, the higher intracellular cAMP concentration decreases the activation

31

of macrophages, concentration of superoxide anions and inhibits the release of lysosomal

32

enzymes from polymorphonuclear cells

33

dependent manner

34

mechanisms, especially to the increase in prostaglandin E2 production, inhibition of natural

35

killing cells18, reduction of the TNF- α expression and increased production of TGF-β

36

(transforming growth factor beta), which leads to a reduced action of Th1 cells 15.

37

Different fiber forming polymers are often used as drug carriers, absorbents or as moisturizers

38

in wound dressings19, 20. Natural polysaccharides, such as regenerated cellulose (viscose),

39

cellulose derivatives and alginate, are as part of various formulations (e.g., foams, hydrogels,

40

non-woven materials) among the most common functional parts of different modern wound

41

dressings

42

sustained drug release, make alginate and chitosan (and its derivatives) highly interesting for

43

the development of functional wound dressings

44

derivative of the chitosan, is permanently charged and water soluble, and has been previously

45

shown as suitable for preparation of controlled delivery formulations 25. Alginic acid (ALG) is

46

a water soluble anionic polysaccharide isolated from seaweed and various microbial sources,

47

and is mostly used in the form of a calcium salt. In contact with the wound exudate (with an

48

excess of sodium ions) an exchange of Na+ and Ca2+ ions takes place, which leads to the

49

formation of a viscous gel 23. The gel enhances the autolytic cleansing activity in the wound

15

. The inhibition of TNF-α takes place in a dose

17

. The anti-inflammatory effect of PTX is also related to other

21

. Their already observed positive effect on wound healing and suitability for

22-24

. N, N, N-trimethyl chitosan (TMC), a

ACS Paragon Plus Environment

Page 4 of 58

Page 5 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

26

. The increase of Ca2+ ions in the wound leads to an

50

and decreases the bacterial count

51

improved hemocompatibility and to an increased rate of fibroblast proliferation 27, 28.

52

Although multilayered and multifunctional wound dressings, especially the ones, created

53

through the layer-by-layer (LbL) technique, are not a novelty in wound care

54

products do not address the challenging issues in wound treatment, such as controlled

55

therapeutic action or wound type specific healing 30, 31. The LbL technique has been perfected

56

in the last decade and already successfully applied in different fields of research

57

hard to overlook the potential of LbL in development of novel drug delivery systems that go

58

beyond a simple passive diffusion based delivery, but provide different levels of control over

59

the release

60

multilayers for the controlled delivery of different anti-inflammatory drugs

61

from previous LbL approaches to prepare nanofilms for controlled drug delivery, as well as

62

considering the still many unexploited potentials in development of novel drug/material

63

combinations as multilayered multifunctional wound dressings, served both as the foundation

64

for this study.

65

Based on the above mentioned, the aim of this study was the development of a platform for

66

the design and testing of the potential of novel wound dressings, in the form of multilayers

67

with an incorporated drug. Using a combination of a biocompatible cationic TMC and anionic

68

ALG polysaccharides, and a potent anti-inflammatory drug PTX, we prepared and

69

characterized an advanced wound dressing for the treatment of chronic venous ulceration

70

based on controlled delivery of PTX. Among others, its potential for future use in wound care

71

can be deduced from the different in vitro cell studies on human skin and immune cells,

72

showing an improved cell viability and diminished inflammation after exposure to the

73

developed system, respectively.

29

, existing

32, 33

. It is

34-36

. Recently, several studies have also focused on the use of LbL-based

74

ACS Paragon Plus Environment

30, 37-39

. Learning

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

75

2

76

2.1

77

N,N,N-trimethylchitosan chloride (TMC 66, Mw: 90 kDa, degree of acetylation (DA): 32%,

78

degree of cationization (DSNMe3+Cl-: 66%)) with medical grade quality was purchased from

79

Kitozyme S.A. (Herstal, Belgium). Sodium salt of alginic acid (ALG) and PBS buffer tablets

80

were purchased from Sigma-Aldrich (Maribor, Slovenia) and used as received. A so called

81

Soft Alignattamponade (SeaSorb, Coloplast, Denmark) was used as the substrate for the

82

preparation of the multilayers on a “real” wound dressing. Milli-Q (18.2 MΩ cm at 25 °C)

83

water from a Millipore water purification system (Billerica, USA) was used for all sample

84

preparations. Quartz crystal microbalance (QCM) crystals coated with SiO2 (QSX303) were

85

purchased from LOT-Oriel, Germany. All chemicals were used without further modification.

86

Different cell lines were used for the safety and efficiency testing, namely the human skin

87

derived fibroblast cell cultures (ATCC-CCL-110, Detroit 551, and ATCC-CCL-171, MRC-5,

88

both from LGC Standards, UK) and THP-1 human monocytes obtained from Cell Line

89

Services were cultured in Roswell Park Memorial Institute (RPMI, Gibco, USA).

EXPERIMENTAL Materials and methods

90 91 92

2.2

Substrate cleaning and multi-layered polysaccharide nanofilm preparation with pentoxifylline (PTX) drug

93

2.2.1 Substrate cleaning

94

Slicon wafers (Si-wafers, Topsil, Germany) with (100) surface orientation were cut into

95

pieces of 1 x 1 cm2 and used as base-substrates for the multilayer preparation. In brief, the Si-

96

wafers were cleaned with ethanol, rinsed with Milli-Q water and immersed into a “piranha”

97

solution of 1:3 (v/v) H2O2 (35%)/H2SO4 for 1 h. After that, they were soaked in Milli-Q water

98

for another hour, washed with Milli-Q water and blow-dried with N2 gas. The cleaned wafers

99

were then used for the subsequent deposition of TMC and ALG.

ACS Paragon Plus Environment

Page 6 of 58

Page 7 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

100

2.2.2 Multilayer preparation

101

Briefly, 50 µL of TMC (0.1%, w/v, dissolved in 150 mM NaCl electrolyte) was deposited on

102

the static Si-wafers, which was then rotated for 30 s with a spinning speed of 3000 rpm and

103

acceleration of 2500 rpm/s. Subsequently, 50 µL of ALG (0.1%, w/v, dissolved in 150 mM

104

NaCl electrolyte) was spin coated on the TMC layer using the same preparation parameters as

105

described above. Likewise, two more bilayers of TMC/ALG were created. Each coated layer

106

(TMC or ALG) was designated with the numbers 1, 2, or 3, for the number of layers in

107

respective samples (i.e., 3TMC, 2ALG etc.).

108

2.2.3 Drug loading

109

Pentoxifylline (PTX) drug was incorporated into each bilayer by a simple dropping approach.

110

50 µL of PTX, dissolved in Milli-Q water at different concentrations (1, 5, 10, 15, 20

111

mg/mL), was deposited on the TMC layer in each bilayer and dried at 40 °C for 2 h. As soon

112

as the PTX drug solution was dried, the next layer of ALG was created by spin coating as

113

described in section 2.2.2. Afterwards, 50 µL of Milli-Q water was deposited on the final

114

ALG layer and spin coated using the same parameters as mentioned in section 2.2.2. To create

115

multilayers with PTX drug on ‘real’ alginate wound dressing (sterile SeaSorb of 1 x 1 cm2

116

size), instead of Si-wafers, the same procedure as stated before was used.

117

The resulting multi-layered film structure is shown in Figure 1. The final sample names

118

represent the number of respective layers and the number of PTX depositions (xTMC, yALG,

119

zPTX), as well as the used PTX concentration for the respective sample (i.e., 3TMC-3ALG-

120

3PTX_15 for the sample composed of three bilayers, whereas PTX with the starting

121

concentration of 15 mg/ml, was added thrice). The sample prepared on the alginate substrate,

122

was denoted as ALG_3TMC-3ALG-3PTX_20. As seen from the name, in this sample, PTX

123

was added thrice using a concentration of 20 mg/ml.

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

124 125

Figure 1: Schematic depiction of the prepared multi-layered films.

126 127

2.3

128

The wettability of TMC and ALG coated layers was measured by using Dataphysics contact

129

angle measurement system OCA15+ (Dataphysics, Germany) with the sessile drop method

130

and a drop volume of 3 µl. All measurements were carried out at room temperature.

131

Determination of the SCA was based on the analysis of the drop shape and was performed

132

with the software provided by the manufacturer (software version SCA 20). All the

133

measurements were performed on at least three independent substrates with a minimum of

134

three drops per surface and. The results are reported as average values with standard errors.

Contact angle (CA) measurement

135 136

2.4

137

ATR-IR spectra were recorded using an Agilent Cary 630 FTIR spectrometer with the

138

diamond ATR module at a scan range of 4000–650 cm-1 with a step of 1 cm-1. The scans were

139

performed on three different places in 8 repetitions on either for each sample surface, as well

140

as after preparation of each respective layer.

Attenuated total reflectance infrared (ATR-IR) spectroscopy

141

ACS Paragon Plus Environment

Page 8 of 58

Page 9 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

142

2.5

143

Layer thickness of TMC and ALG coated films was determined by profilometry using a

144

DEKTAK 150 Stylus Profiler from Veeco (Plainview, NY, USA). The scan length was set to

145

1000 µm over the time duration of 3 s. The diamond stylus had a radius of 12.5 µm and the

146

force was 3 mg with a resolution of 0.333 µm/sample and a measurement range of 6.5 µm.

147

The profile was set to hills and valleys. Prior to surface scanning, the coated layers were

148

scratched to remove the TMC/ALG films in order to determine the thickness of the coating

149

using a step-height profile. The thickness was determined at 3 independent positions. The

150

samples were measured after each coating of either TMC or ALG.

Profilometry

151 152

2.6

153

A QCM-D instrument (model E4) from Q-Sense, Gothenburg, Sweden was used to calculate

154

the mass of each deposited layer. The instrument simultaneously measures changes in the

155

resonance frequency (∆f) and energy dissipation (∆D) when the mass of an oscillating

156

piezoelectric crystal changes upon increase/decrease in the mass of the crystal surface due to

157

the added/deduced sample mass. Dissipation refers to the frictional losses that lead to

158

damping of the oscillation depending on the viscoelastic properties of the material. For a rigid

159

adsorbed layer that is fully coupled to the oscillation of the crystal, ∆fn is given by the

160

Sauerbrey equation40 (1):

Quartz crystal microbalance with dissipation measurements (QCM-D)

∆m = C

∆f n n

(1)

161

where ∆fn is the observed frequency shift, C is the Sauerbrey constant (-0.177 mg·Hz-1·m-2 for

162

a 5 MHz crystal), n is the overtone number (n = 1, 3, 5, etc.), and ∆m is the change in mass of

163

the crystal due to the adsorbed layer.

164

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

165

2.7

166

The surface morphology of the samples was characterized by atomic force microscopy (AFM)

167

in tapping mode with an Agilent 7500 AFM multimode scanning probe microscope (Keysight

168

Technologies, Santa Barbara, USA). The images were acquired after drying the samples with

169

N2 gas. The images were scanned using silicon cantilevers (ATEC-NC-20, Nanosensors,

170

Germany) with a resonance frequency of 210–490 kHz and a force constant of 12–110 N m-1.

171

All measurements were performed at room temperature. All images were recorded with a

172

resolution of 2048 x 2048 pixels and were processed using the freeware Gwyddion software

173

package.

Atomic force microscopy

174 175

2.8

176

In vitro drug release studies were performed using an Automated Transdermal Diffusion Cells

177

Sampling System (Logan System 912-6, Somerset, USA). The drug-loaded samples were

178

placed heads up into the Franz diffusion cell. The receptor compartment was filled with PBS

179

solution (pH 7.4) and its temperature was maintained at 37 °C. During the dissolution testing,

180

the medium was stirred continuously with a magnetic bar at 50 rpm. Samples were collected

181

over a period of six days at different time intervals (1, 5, 10, 20, 30, 60, 120, 180, 240, 360,

182

1440, 2880, 4320, 5760, 7200 and 8640 min), while the released/dissolved PTX concentration

183

in the receptor medium was determined using UV-Vis spectrophotometry (Cary 60 UV-

184

Visible Spectrophotometer, Agilent, Germany) by quantification of the absorption band at

185

276 nm. The withdrawn sample volumes were replaced by fresh PBS solution. Due to sample

186

withdrawal, followed by sample dilution through media replacement, sink conditions were

187

ensured. In the calculation of concentrations using the Beer-Lambert law, this dilution was

188

accounted for. All release studies were performed in three parallels. For all obtained release

In vitro drug release

ACS Paragon Plus Environment

Page 10 of 58

Page 11 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

189

results, the confidence interval was determined as ±/√ , where t is a Student's t-

190

distribution, s is the standard deviation, and x is the number of measurements.

191

In order to fit the release results and consequently evaluate the release kinetics, two well-

192

known models to describe the release from different pharmaceutical formulations, were

193

applied. Namely, the zero-order kinetics as shown in equation (2) and the modified

194

Korsmayer-Peppas model, equation (3) 41.

195

Zero order kinetics  =  + 

(2)

196

where Mt is the amount of drug dissolved in time t, M0 is the initial amount of drug in the

197

solution (most time M0 = 0) and k0 is the zero-order release constant expressed in unit’s

198

concentration/time.

199

Modified Korsmayer-Peppas model

 = ∙  +  

(3)

200

where Mt is the fraction of drug released at time t, M∞ is the total amount of drug in the

201

system, k is the constant of apparent release, n the diffusion exponent and b the amount that

202

can be associated with the burst release.

203 204

2.9

205

2.9.1 Preparation of extracts

206

The extraction was carried out in compliance with ISO10993-5 and ISO 10993-12 regulations

207

(10993-5 AAI. Biological evaluation of medical devices - Part 5: Tests for in vitro

208

cytotoxicity. 2009.10993-12 I. Biological evaluation of medical devices – Part 12: Sample

209

preparation and reference materials. 2007) by incubation of 3cm2 material per ml cell culture

210

medium for 24h at 37°C.

Cell based assays

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

211

2.9.2 Cells and exposures

212

MRC-5 human fibroblasts (ATCC-CCL-171) were cultured in in Minimal Essential Medium

213

+ Earle’s salts (MEM, Gibco, USA), 10 wt.% fetal bovine serum (FBS, GE Health Sciences,

214

UK), 2mM L-glutamine, 1 wt.% penicillin/streptomycin at 37°C and 5 wt.% CO2. THP-1

215

human monocytes obtained from Cell Line Services were cultured in Roswell Park Memorial

216

Institute (RPMI, Gibco, USA) 1640 medium,10 wt.% FBS, 2mM L-glutamine, 1 wt.%

217

penicillin/streptomycin.

218

MRC-5 cells were exposed to the pure eluates, 1:2, 1:5, 1:10 and 1:20 dilutions with MEM +

219

10 wt. % FBS. THP-1 cells were exposed to eluates in 1:2, 1:4, 1:10 and 1:20 dilution with

220

RPMI 1640 + 10 wt.% FBS.

221 222

2.9.3 Viability/cytotoxicity screening in contact with in eluates

223

MRC-5 cells/well of a 96 well were seeded 24h prior to the exposures to the eluates. Cell

224

density was 16,000/well for 24h, 13,000 for 48h and 11,000 for the 72h exposures. The

225

different densities were needed to obtain the subconfluent growth conditions suggested for

226

cytotoxicity testing. Treatment of cells with 2µl 70 wt. % EtOH + TritonX100 (1+1) for 10

227

min prior to the measurement of viability was used as positive control. After exposure to the

228

eluates for 24h, viability was determined using the measurement of dehydrogenase activity

229

(CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay, Promega, USA) and ATP

230

content (CellTiter-Glo Luminescent Cell Viability Assay, Promega, USA).

231 232

2.9.4 CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay/MTS

233

The assay was used according to the instruction in the user manual. In short, MTS solution

234

and the PMS solution were thawed, 100 µl of the PMS solution was mixed with 2 ml of MTS

235

solution and 20 µl of the combined MTS/PMS solution was added to 100 µl of each well.

ACS Paragon Plus Environment

Page 12 of 58

Page 13 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

236

Plates were incubated for 2 h at 37°C and 5 wt.% CO2 in a cell incubator. Absorbance was

237

read at 490 nm on a plate reader (SPECTRA MAX plus 384, Molecular Devices, USA). In

238

parallel, cells were viewed by bright-field microscopy to confirm the MTS data. Cell viability

239

was calculated according to the following formula (4):

ℎ  % = 100 ×

$%&'()* − $%&'()*  490 3 $,-.-) − $/)&0

(4)

240

CellTiter-Glo Luminescent Cell Viability Assay for ATP content was used according to the

241

manufacturer’s instruction. Plates were equilibrated to room temperature for approx. 30

242

minutes and reconstituted CellTiter-Glo Reagent was added 1:1 to the amount of cell culture

243

medium present in each well. Plates were shaken for 2 min and incubated for additional 10

244

min at RT before well contents were transferred to a luminescence compatible 96 well plate

245

and luminescence was read on a Lumistar (BMG LabTech, USA).

246 247

2.9.5 Viability/cytotoxicity screening in direct contact

248

MRC-5 cells (400,000 cells for 24h; 332,500 cells for 48h, and 266,000 cells for 72h

249

exposure) were seeded on glass coverslips (control for optimal cell growth) or on PTX loaded

250

multilayers and not loaded multilayers placed in a conventional plastic well. After 24h, 48h,

251

and 72h of incubation cells were viewed by bright field microscopy. After 72h growth

252

substrates with the cells were transferred to another well for determination of viability using

253

dehydrogenase activity, cells in the glass bottom plate were analyzed in the well. Cells were

254

removed from the substrates and cells counted using CASY TT cell counter (Innovatis Roche,

255

Switzerland).

256 257

2.9.6 Measurement of TNF-α secretion

258

1x10E6 THP-1 cells were seeded in 12-wells and treated with eluates in different

259

concentrations alone and in combination with the inflammatory stimulus 500 ng/ml

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

260

lipopolysaccharide (LPS, Escherichia coli 055:B5, Sigma, Germany) for 24h. The release of

261

the cytokines was measured using the TNF-α ELISA set from BD Biosciences (BD

262

OptEIA™, USA) according to the protocol given by the producers. In short, plates were

263

coated with the respective anti- TNF-α (capture) antibody, exposed to standards and samples

264

(in the appropriate dilution), incubated with the biotinylated detection antibody plus

265

streptavidin-coupled horseradish peroxidase and finally with the peroxidase substrate

266

tetramethylbenzidine. After termination of the reaction by addition of 2N sulfuric acid

267

absorbance was read at 450 nm with correction at 570 nm on a SPECTRA MAX plus 384

268

photometer (BMG LabTech, USA).

269 270

2.9.7 Exposure to samples from the in vitro release testing

271

To perform biocompatibility (according to ISO 10993-5 standard) testing with the human skin

272

derived fibroblast cell culture (ATCC-CCL-110, Detroit 551, LGC Standards, UK), solutions

273

of respective samples, withdrawn at the desired time intervals during the release testing, were

274

incubated with the fibroblast cell culture in P96 microtiter plates. Each well was filled with

275

cell suspension containing 60,000 cells and after 24 h, when the cells attached, it was

276

supplemented with the dissolved sample solutions, as described above. The solutions used

277

were diluted in a ratio of 1:2 in the cell culturing media (Advanced Dulbecco’s modified

278

Eagle’s medium (ADMEM, Gibco, Grand Island, NY, USA)), supplemented with 5 wt.%

279

FBS. Cytotoxic effects on the cell culture were observed after 24 h of incubation at 37 °C and

280

5 wt.% CO2. Cell viability was determined via the reduction reaction of the tetrazolium salt

281

MTT (3(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide)42.

282 283

3

RESULTS AND DISCUSSION

ACS Paragon Plus Environment

Page 14 of 58

Page 15 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

284 285

Biomacromolecules

3.1

Multilayer characterization: layer thickness, roughness, wettability, composition and morphology

286

Understanding the growth, the surface and the physicochemical properties of multi-layered

287

systems built on 2D substrates is a highly important base knowledge for design and

288

development of ‘real-3D’ materials such as wound-dressings and materials for tissue

289

engineering applications. Therefore, we carefully analysed the layer thickness (t), roughness

290

(r), mass (m), wettability and morphology of the multilayer polysaccharide nanofilms created

291

from the alternating deposition of TMC and ALG. Figure 2 shows the results of the measured

292

layer thicknesses, the respective sample roughness’s (determined by profilometry

293

measurements) and the Sauerbrey (dry)-mass for each spin coated layer and also for the rinsed

294

multilayer. The total thickness increases linearly with the number of layers deposited; which

295

is also reflected in the roughness (Figure 2a). The layer thickness is increased from ca. 90 nm

296

(1TMC) to ca. 280 nm after three bilayers. The obtained layer thickness for the second and

297

third TMC deposition is almost the same (2TMC: 43 nm, 3TMC: 42 nm). In the case of ALG,

298

the layer thickness decreases with increasing deposition step (1ALG: 40 nm > 2ALG: 34 nm

299

> 3ALG: 29 nm). The roughness values slightly increase as the number of deposition steps

300

increases for both TMC and ALG. Upon rinsing with water, the reduction of film thickness

301

(24%, t: 220 nm) and roughness (r: 13.5 nm) is clearly visible, indicating that all loosely

302

bound materials are removed and a smooth film is formed. The mass of each deposited layer

303

was also estimated using QCM-D (Figure 2b). The latter is a highly sensitive and suitable

304

technique, often used to determine the mass of dry and rigid adsorbed layers directly from the

305

change in frequency using the Sauerbrey equation (1), in particular, when the change in

306

dissipation is below 2 x 10-6

307

0.22 ± 0.003 x 10-6 for each layer. It has to be noted that the spin coated layers were also

308

always dried with the stream of nitrogen gas before they were assembled into QCM-D

43, 44

. In our case, the observed change in dissipation is less than

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

309

chambers for the measurements of frequency and dissipation change. The results of Sauerbrey

310

mass is shown in Figure 2b. These depict that the mass (µg/cm2) also increases linearly with

311

respect to deposition steps as in the case of layer thickness and roughness measurements. The

312

Sauerbrey mass for the 1TMC layer is 932 ± 12 µg/cm2. For the 2TMC and 3TMC layer the

313

deposited mass remained constant 400 ± 15 µg/cm2, which is 55% less than the mass

314

estimated for the first layer. In the case of ALG deposition, the mass is decreased with the

315

increasing number of deposition steps. The mass of the multilayer is also reduced up to 29%

316

after rinsing with water. The above results are in excellent correlation with the thickness

317

values obtained from profilometry measurements, indicating that QCM-D is a reliable and

318

direct technique for the measurements of deposited dry layers.

319 320

Figure 2: Layer thickness and roughness (a), and QCM-D dry mass (b) of multilayer

321

polysaccharide nanofilms assembled from the oppositely charged TMC and ALG.

322 323

The successful alternating coating of TMC and ALG was verified by static water contact

324

angle SCA(H2O) measurements (Figure 3); the latter gives meaningful information to show

325

the hydrophobic/hydrophilic characteristics of the coating. The hydrophilic film surface

326

(ALG) represents a lower contact angle value whereas the hydrophobic film surface (TMC)

327

exhibits a greater contact angle value. In general, the contact angle value (i.e., surface

ACS Paragon Plus Environment

Page 16 of 58

Page 17 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

328

wettability) is sensitive to chemical functionalities of the outermost layer. The measured

329

SCA(H2O) exhibits a zigzag feature with the number of deposited layers, implying the

330

alternating coating of TMC and ALG on the surface. With the first TMC coating the

331

SCA(H2O) increased to 23.2 ± 0.7° in comparison to SiO2 surface (SCA(H2O): 10 ± 0.2°, data

332

not shown). This result is in accordance with the previous work where the TMC layer

333

adsorbed on cellulose substrate exhibited a lower contact angle (SCA(H2O): 24 ± 1°)45. The

334

subsequent ALG layer results in a decreased contact angle. These trends of increase and

335

decrease in SCA(H2O) is also repeated for next two bilayers, indicating that ALG is more

336

hydrophilic compared to TMC. The increased hydrophobicity (i.e., contact angle) for the

337

second and third TMC layers can be attributed also to the higher surface roughness as shown

338

in Figure 2a. After rinsing with water, the multilayer is becomes more hydrophilic with an

339

SCA(H2O) of 20.8 ± 0.1. An explanation can be the combination of change in surface

340

composition, reduced layer thickness and roughness (Figure 2). As a result of rinsing, various

341

functional groups such as -OH, -COOH, -NH2, and -N(CH3)3 originating from both TMC and

342

ALG, which are hydrophilic, can be exposed on the surface.

343 344

Figure 3: Water contact angle of multilayer polysaccharide nanofilms assembled from the

345

oppositely charged TMC and ALG.

346

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

347

Results from ATR-IR measurements of multilayer built up on QCM-D Au-sensors (without

348

PTX incorporation) are shown in Figure 4a. The spectra show three main peaks, two of them

349

characteristic for TMC (1~1564 cm-1 for N-H, and 2~1479 cm-1 for C-H bending vibrations)

350

46

351

of the mentioned peaks indicate an increase in respective polymer content, indirectly

352

confirming the successful alternating coating of TMC and ALG layers. The latter is also in

353

agreement with the results of CA, QCM-D and profilometry measurements, where increasing

354

mass, thickness and hydrophilicity/hydrophobicity were observed as the result of multilayer

355

formation. The spectrum of PTX incorporated films exhibits several characteristic peaks,

356

which can be used for identification of its presence in the samples (Figure 4b).

, and one for ALG (3~1024 cm-1 for C-O stretching vibrations)47. The increasing intensities

357

358

ACS Paragon Plus Environment

Page 18 of 58

Page 19 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

359

Figure 4: ATR-IR spectra of multilayer polysaccharide nanofilms prepared (a) without and

360

(b) with PTX incorporation at different concentrations. The spectra of multilayers built on

361

alginate dressing and pure PTX drug is shown in (b).

362 363

As seen from Figure 4b, the characteristic peaks for PTX (1701 and 1658 cm−1 for –CO, and

364

amide –CO stretching modes) 48 are present in all deposited layers in addition to the peaks of

365

polysaccharides, indicating successful PTX incorporation. Increasing peak intensities are an

366

expected result of an increasing amount of PTX in respective samples. Figure 4b also shows

367

the spectra for the sample, where an alginate dressing was used as a substrate instead of the

368

Si-wafer. In this case, also the characteristic peaks PTX peaks are observed again confirming

369

the successful PTX incorporation.

370 371

Figure 5: AFM height images of multilayer polysaccharide nanofilms, incorporated with

372

PTX at different concentrations. Top: 1 x 1 cm2 and bottom: 5 x 5 cm2.

373 374

The morphology of multilayers incorporated with PTX at different concentrations is shown in

375

Figure 5. It can be observed that regardless of the PTX content, at lower PTX concentration

376

(1 mg/mL), a rather smooth surface with a roughness in the range of 2 nm is observed in

377

contrast to multilayers prepared without PTX (not shown), which showed a rough surface

378

with a higher roughness (RMS: ~ 6 nm). These changes (morphology and roughness) clearly

379

indicate that the incorporated PTX has influenced the surface characteristics of the film

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

380

already at the lowest concentration. Although the roughness differences are not significant

381

except for lowest PTX concentration, the observed morphology is different for each sample. It

382

is suggested that, at higher concentrations, the PTX molecules are packaged tightly and

383

organized differently in the multilayer built up leading to surfaces with differently formed

384

structures. The samples with the highest amount of incorporated PTX (20 mg/mL), exhibit

385

additional surface features, an indication that the increasing drug amount leads to formation of

386

bigger PTX aggregates. Since these seem to be still in the nanorange, this have no significant

387

influence on the overall sample roughness. Nevertheless, the latter indicates that a further

388

increase in the incorporated amount of PTX could result in even bigger agglomerates that

389

could significantly influence the overall multilayer film stability. Finally, it can be observed

390

that all samples (regardless of the PTX content) exhibit features that could present nano-holes

391

or pores in their structure. This could significantly influence the release performance of such

392

materials. This aspect is in more detail discussed below in section 3.2, describing the in vitro

393

drug release results.

394 395

3.2

396

Multi-layered dressings are commonly employed in clinical wound care for treating chronic

397

wounds49, 50. For this purpose, different commercial materials are combined on site in the

398

form of a “sandwich”. Such an approach enables combining different properties of respective

399

layers (ensuring appropriate moisture, drug delivery, air permeability etc.) to maximize

400

healing efficiency

401

composed of PTX containing bilayers based on TMC and ALG, two well-known

402

polysaccharides in wound related applications52, 53. Such a layered structure with multiple

403

functionalities and different physicochemical properties was chosen in order to suit the

404

treatment of the chronic venous ulceration for individual patients. This can be achieved

Controlled pentoxifylline delivery – possible clinical applicability?

31, 51

. In this study we prepared multi-layered model wound dressings

ACS Paragon Plus Environment

Page 20 of 58

Page 21 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

405

through a possible adjustment of the PTX concentration (and hence the dose of the drug), its

406

effective and prolonged delivery up to five days without the need to change the dressing, as

407

well as exploiting the overall wound healing promoting effects of the used polysaccharides

408

TMC and ALG. Overall, such a dressing could significantly lower the necessary treatment

409

costs per patient for this type of wound.

410

In order to test the possible applicability of the chosen preparation methodology in a real

411

clinical setting, we prepared the same multilayers with PTX also on a non-woven alginate

412

dressing (SeaSorb from Coloplast, which is clinically used) and compared its release

413

performance with the model system built on Si-wafers. The obtained results from the in vitro

414

release testing are shown in Figure 6. Four important findings are presented in different

415

diagrams describing our results. These are explained in the following subchapters.

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

416 417

Figure 6: Results from the in vitro release study: a) PTX mass as a function of time, b)

418

linearity testing of the dependence between the drug loading and released PTX mass, c) the %

419

of release PTX as a function of time, d) first derivatives of the release data for all samples, e)

420

fitting of the release profiles up to 360 min using the Zero order model, and f) fitting of the

421

release data from 360 min to 8640 min using the Korsmayer-Peppas model.

422

ACS Paragon Plus Environment

Page 22 of 58

Page 23 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

423

3.2.1 The cumulative released DCF mass as a function of time

424

Figure 6a shows the results from the cumulative amount (mg/cm2) of released PTX from

425

respective samples as a function of time. The most likely general scenario to describe the

426

release profiles is that most of the PTX was relatively loosely packed inside the layers without

427

any significant interaction with the host materials. Here it has also to be stated that the final

428

step in the preparation of the multi-layered samples, namely the rinsing with water, followed

429

by spin coating, presumably led to a homogenous PTX distribution through the layers (see

430

Figure 7).

431 432

Figure 7: Schematic depiction of the influence of the final multilayer preparation step on

433

PTX distribution in the sample. Black arrows show the presumable burst like release, whereas

434

the red arrows present the slower release after 360 min.

435 436

This part of the incorporated drug is released in a “burst” like fashion (evident for the first

437

couple of minutes for all samples). The amount of released PTX due to this, and hence the

438

duration of this release part, differs for respective samples, according to the different

439

incorporated PTX concentrations. Namely, the higher the incorporated PTX dose, the bigger

440

the overlap of this initial release region between samples of increasing incorporated PTX

441

amounts. Following this initial fast release, the release mechanism of PTX dissolution is

442

presumably for the most part governed by the concentration gradient between the material

443

interior and the release media, and hence its diffusion from the bulk material to the drug

444

dissolution at the material surface, and finally to the bulk solution. This part of PTX is likely

445

to interact with the host materials as well. Presumably this is due to possible hydrogen

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

446

bonding (carbonyl and amine groups from PTX, hydroxyl and carboxyl groups from ALG,

447

and hydroxyl and amine groups in TMC). A smaller contribution to the overall dissolution

448

process is due to the lower parts of the samples, where PTX has to either penetrate through all

449

of the above layers or is released sideways from the coatings (see the schematic depiction of

450

this scenario in Figure 7).

451

In addition, two important characteristics can be noted by presenting the release results as the

452

cumulative release drug mass (Figure 6a). Firstly, it is evident that by increasing the PTX

453

amount in the samples, the corresponding amount of released PTX can be increased without a

454

significant effect on the overall release kinetics (see further discussion below). Hence, the

455

proposed preparation process allows us to fine-tune the final released dose of PTX by a very

456

simple method, namely increasing the concentration of PTX in the solution during

457

preparation. The potential therapy using such materials would be similarly efficient in

458

lowering inflammation (targeted PTX action in this case) during the release, whereas the final

459

dose, which is connected with the individual patient (patient’s physical characteristics), can be

460

fine-tuned without significant effect on the overall release kinetics, hence inflammation will

461

be lowered with the same clinical efficiency for the respective patient. Since the main purpose

462

of this study was the preparation of possible clinically applicable multilayered wound

463

dressings for treatment of chronic venous ulcerations, it was important to somehow consider

464

the actual applicability of the proposed preparation approach. To validate our research study,

465

we prepared the same multilayers as on Si-wafer (model nanofilms) also on a clinical used

466

alginate dressing. For this purpose, we incorporated in it the highest PTX concentration used

467

in the model systems (20 mg/mL, Figure 6a) and compared the release kinetics with the

468

model systems for the same concentration. Slightly unexpectedly, the shape of the release

469

profiles of the model films and the clinically more realistic sample are almost identical.

470

Although there is a difference between the overall performance of this sample, since it

ACS Paragon Plus Environment

Page 24 of 58

Page 25 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

471

overlaps with the release curve for the model system containing a lesser PTX amount (15

472

mg/mL compared to the targeted 20 mg/mL), this result is nevertheless very promising. This

473

difference probably originates from the distribution of PTX after the final rinsing during the

474

spin coating. For the “real” system PTX can be distributed through the whole bulk of the

475

material (both the multilayers and the substrate alginate dressing) in contrast to the model

476

multilayered system, where there is no possible uptake of PTX into the Si-wafer substrate.

477 478

3.2.2 Analysis of the released PTX dependence on the incorporated PTX dose

479

In order to evaluate the possible control over the released mass of PTX in respective samples

480

through the change of the initial concentration of PTX solution to be incorporated, we plotted

481

the released PTX masses at two different times. The chosen time points were after 6h of the

482

release, and after 5 days, and plotted them as a function of the starting PTX concentration

483

(ranging from 1 mg/mL to 20 mg/mL). Figure 6b shows the plotted results. Since we could

484

immediately observe a possible linear trend at both mentioned withdrawal times, we fitted

485

these results using a linear fit. The results are shown as part of Figure 6b. Based on the ~99%

486

and ~97% R2 values, we could confirm that the proposed, relatively simple tailoring of the

487

preparation procedure, is quite effective for controlling the final released amount of PTX,

488

hence providing a great tool for clinicians to adjust the PTX therapeutic dose for individual

489

patients.

490 491

3.2.3 The percentage of released PTX as a function of time

492

Figure 6c shows the results in the form of the percentage of PTX released as a function of

493

time. This percentage was calculated by using the final released amount (after six days when

494

the concentration stabilized). The most important findings from Figure 6c complements the

495

above discussed (section 3.2.1). Namely, not only can the dose be increased (even adjusted)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

496

by simply increasing the PTX concentration for “loading” into the multilayers, but that

497

although the incorporated PTX amount was increased, all incorporated PTX in the respective

498

samples was released in almost the same time frames. The latter can be seen in the very

499

similar release profiles in Figure 6c, reaching the end point of release after six days. This

500

finding is very important, if we consider potential clinical application, where in accordance

501

with the patients’ physical characteristics (mostly mass and overall health assessment), the

502

dose of a drug has to be adjusted. To put the prepared multi-layered wound dressings into a

503

more comprehensible perspective, we should here again mention that PTX provides an anti-

504

inflammatory activity, which can be provided by our system in a localized manner, namely

505

directly at/in the wound, where the drug can reach high concentrations. The latter could

506

ensure a much-improved efficacy, since the activity of PTX is dose dependant, as well as by

507

lowering the potential degradation of the drug (more likely through other types of

508

administration, where the drug has to cross the liver, the major organ for metabolism, prior to

509

reaching the bloodstream). PTX has a relatively low half-time (45-60 min), which can be

510

overcome by this type of administration. Finally, local delivery would also lead to much less

511

unwanted effects that mostly accompany systemic administration (per os, even intravenous).

512

The latter is especially important for drugs like PTX, which, although very effective, possess

513

a wide range of different pharmacodynamic activities. From Figure 6c it also again evident

514

that the multi-layered dressing prepared on the alginate substrate, resembling the more

515

realistic clinically applicable wound dressings, exhibits the same release profile. This once

516

more confirms the above statement that the model and the real system possess a similar

517

release performance.

518 519

3.2.4 Evaluation of the release mechanism

ACS Paragon Plus Environment

Page 26 of 58

Page 27 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

520

Our objective was also to understand the release kinetics from our nanofilm multi-layered

521

coating systems from the mechanistic perspective. For this purpose, we applied several

522

models to describe the respective release profiles

523

studied different materials and their release performances before57-62. Unfortunately, as simple

524

as our system may seem (schematically depicted in Figure 1 and Figure 6), no single

525

available model was able to describe our profiles completely with the desired statistical

526

weight. Nevertheless, if the obtained release profiles are divided into two sections (dividing

527

the faster initial release from the steadier release at higher release times), fitting with available

528

models get more effective. Such division into two sections can be confirmed also by

529

calculating the first derivatives of the release profiles as shown in Figure 6d. Considering the

530

above discussion and the successfully applied release models (Zero-order and modified

531

Korsmayer-Peppas to account for the initial burst release), the two release regions could be

532

the initial diffusion controlled release (with a burst in the first minutes), and the following

533

second part, where the remainder of the PTX is released in a linear fashion (regardless of the

534

remaining PTX concentration in the samples) (Figure 6e and f).

535

The first derivatives calculated from the release data clearly confirm the above assumptions.

536

Namely, they show that all release profiles show the two release regions, and the distinction

537

point at 360 min of the release (inset graph in Figure 6d). Therefore, addressing the release

538

region before and after this part, seems to be appropriate. Here we have to mention also that

539

for the purpose of fitting, the zero-order kinetics model requires the data to be presented and

540

fitted in the form of the cumulative drug release (in our case this means the released PTX

541

mass until the chosen time). On the other hand, the Korsmayer-Peppas model fits release data

542

in the form of the fraction of the released drug amount in certain time point, which compared

543

with the final released amount (in our case this means the fraction of release PTX at point tx

544

and its comparison with the final release point at t = 8640 min). Due to the latter, the fitted

54-56

. The authors of the present study have

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

545

results are shown in the form of the two respective graphs, exhibiting the mentioned

546

representation types. Table 1 presents the R2 values for respective samples and respective

547

regions, fitted with the mentioned models. As can be immediately deduced from the table,

548

both types of fitting produce excellent results (according to the calculated R2 values for

549

respective fits).

550 551 552

Table 1. R2 values for the fitted release results for all samples for both regions, using the zero-order kinetics model and the modified Korsmayer-Peppas model, respectively. Fast release part Constant release part (zero Sample/R2 value (Korsmayer-Peppas fit) order kinetics fit) 3TMC-3ALG-3PTX_1 0.98617 0.9954 3TMC-3ALG-3PTX_5 0.98726 0.97407 3TMC-3ALG-3PTX_10 0.97587 0.96388 3TMC-3ALG-3PTX_15 0.99158 0.98109 3TMC-3ALG-3PTX_20 0.98387 0.97533 ALG_3TMC-3ALG-3PTX_20 0.98111 0.98021

553 554

The suitability of the used models to describe the release profiles of the prepared samples,

555

makes sense also from the general description of both models. Korsmayer-Peppas derived a

556

simple relationship that describes the release of drugs from polymeric systems, which has

557

been successfully applied to describe release from several modified release dosage forms.

558

Additionally, the generic equation used to describe this model (the Power law) is applicable

559

for times, where release has not yet reached 60% of the overall amount of incorporated drug

560

63, 64

561

coefficient, which is ideal for the samples in this study. Therefore, the mentioned fits well

562

with our system. The second part of the release profile can be well described with a linear fit,

563

which is in pharmacy referred to as the zero-order model 65. In the latter, the release rate of a

564

respective drug is independent of its concentration. Such release is desired especially in

565

certain classes of medicines, like in pain control, heart and blood pressure maintenance etc.,

566

and therefore also in our wound dressing, where maintenance of the anti-inflammatory action

. Finally, a modified version of this model incorporated also the so called “burst release”

ACS Paragon Plus Environment

Page 28 of 58

Page 29 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

567

for a prolonged time, could lead to an improved healing performance of the chronic venous

568

ulceration. The latter is true also from the clinical perspective, since a prolonged exposure to

569

PTX, and hence its action, improves its overall anti-inflammatory activity 13, 66.

570

As discussed in the section describing the results from the AFM measurements (Figure 5),

571

the surface morphology, although perhaps different in details for respective samples on the

572

nanoscale, exhibits also very similar features on the surface. These most likely represent holes

573

(pores), allowing for a more effective diffusion of PTX from the interior into the release

574

media. These similar surface features between samples are in agreement with the generally

575

similar release profiles obtained for all samples. Finally, the evaluation of the release profiles

576

and discussing possible mechanisms seems to point also to another important characteristic of

577

the prepared samples. Namely that most likely the drug is generally more or less

578

homogenously distributed throughout all layers (regardless of the polysaccharide of the

579

respective layer, Figure 7), which not only allows a better control over the release, but also

580

ensures a lowered risk of possible local drug overdoses that could appear in case of “pealing”

581

off respective layers, exposing a bigger drug amount to the media in a short time.

582 583

3.2.5 Clinical applicability of such materials based on the in vitro drug release performance

584

Finally, let us consider the suitability of the developed wound dressing system for treatment

585

in a real clinical setting. Patients come to the clinics with different states of their wounds that

586

occur in different shapes and sizes. Both mentioned make it a difficult task for the handling

587

doctor to choose and prepare the optimal therapy, as well as to “technically” perform the best

588

wound care. Our system with its controlled release and tailorability of the drug dose, allow for

589

relative simple on site handling and patient specific wound care individualization.

590

Additionally, controlled PTX release, which is exhibited by our system, allows for a

591

controlled anti-inflammatory action, and the dose tailorability, for a high level of personalized

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

592

treatment options. All presented results were also obtained for samples of exact dimensions

593

(namely 1 cm x 1 cm). This means that we know the exact amounts of released PTX also per

594

unit area. This allows for an even more important patient specific optimization, namely the

595

size of the respective wound dressing to be applied for an individual patient, can be easily

596

tailored as well. As an example, based on our system, we calculated the incorporated amount

597

of PTX in two differently sized hypothetical wound dressings (Table 2).

598 599 600 601

Table 2: Total incorporated PTX amounts in the prepared samples in this study and calculated values for a hypothetical wound dressing with the dimensions 10 cm x 10 cm. The values were deduced and hence calculated based on the final release point of respective samples (the completeness of the release was confirmed through IR measurement). Sample/Size of hypothetical dressing 1 cm x 1 cm [mg] 10 cm x 10 cm [mg] 3TMC-3ALG-3PTX_1 0.535 53.5 3TMC-3ALG-3PTX_5 0.967 96.7 3TMC-3ALG-3PTX_10 2.120 212.0 3TMC-3ALG-3PTX_15 4.402 440.2 3TMC-3ALG-3PTX_20 5.275 527.5 ALG_3TMC-3ALG-3PTX_20 4.581 458.1

602 603

3.3

604

In vitro testing based on human tissue derived in vitro cell models (based on skin cells –

605

keratinocytes, fibroblasts, melanocytes, and on immune cells – macrophages or monocytes, as

606

well as a combination thereof) serves as the best indication for developed materials safety and

607

possibly even clinical efficiency for topical, transdermal and open wound applications (either

608

in wound care, drug delivery on and through the skin or in skin tissue engineering). Their use

609

is a direct follow-up to the development of different therapeutic systems, evaluating their

610

increasing complexity with a progressive assessment of desired biochemical response. In

611

comparison with other available studies, which are mostly conducted on either animal-derived

612

or cancer-transformed cells

613

The most important among them is the possibility to obtain results-based conclusions with

614

regard to an actual clinical setting

615

experiments to show the potential of the prepared multilayers to be used in wound care.

Cell based assays

67-70

, using primary human-derived cells has many advantages.

71

. Considering the mentioned, we designed a range of

ACS Paragon Plus Environment

Page 30 of 58

Page 31 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

616 617

3.3.1 Effects of eluates from PTX loaded and unloaded multilayers on viability of fibroblasts

618

MRC-5 fibroblasts exposed to eluates of PTX loaded and unloaded samples did not present

619

changes in cell density or morphology compared to the untreated cultures in brightfield

620

microscopy (Figure 8A-C).

621 622

Figure 8: Morphology of MRC-5 cells exposed to undiluted eluates of PTX loaded (A) and

623

unloaded samples (B) for 48h compared to untreated cells (C).

624 625

However, dehydrogenase activity, as an indication for cell viability, was unchanged in the

626

case of cell exposure to the samples not loaded with PTX (Figure 9). In the PTX loaded

627

samples a biphasic reaction was seen. After 24h, viability was increased at all dilutions

628

compared to untreated cells and after 48h and 72h viability was decreased in cells exposed to

629

undiluted and 1:2 diluted eluates. The difference between untreated cells and the eluates was

630

larger after 72h than after 48h exposure.

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 32 of 58

631 632

Figure 9: Dehydrogenase activity as indication for cell viability of MRC-5 cells exposed to

633

undiluted (pure) and diluted eluates of PTX loaded (LEFT) and unloaded samples (RIGTH) at

634

time points 24h, 48h, and 72h. Activity is normalized to untreated cells as 100%

635 636

These results confirm that the PTX released from the multilayers did not significantly reduce

637

the cell numbers but increased the ATP content after 24h and it markedly decreased at later

638

time points. This controversy can be possibly explained by the action of PTX on

639

mitochondria. For example, endogenous ATP generation has been reported by Feyli et al in

640

relation to an increased motility of spermatocytes after exposure to PTX

641

exposures to PTX, reduced ATP levels in hepatocytes were reported before

642

showed a reduction of ATP levels starting at PTX concentrations of 50 µM. Since the

643

material, in which PTX was embedded, did not reduce viability and since PTX is known to be

644

only minimally cytotoxic at concentrations in the range of 2 mM 74, the action on ATP levels

645

is a likely reason for the disparity of microscopic data and ATP content.

72

. At longer

73

. The authors

646 647

3.3.2 Adhesion and proliferation of fibroblasts in direct contact with the multilayers

ACS Paragon Plus Environment

Page 33 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

648

Upon direct contact with the PTX loaded multilayers, the cell density is decreased. The

649

decrease was moderate after 24h and prominent after 72h. The respective changes can be seen

650

when dehydrogenase activity as an indicator for cell viability (Figure 10A) is used and when

651

cell numbers are determined (Figure 10B). Typical changes in cell morphology are also seen

652

(Figure 11). While fibroblasts cultured on glass showed the typical elongated form (Figure

653

11A), cells on the sample material formed cell clusters, which is not typical for this type of

654

cells. Furthermore, cell density was markedly reduced in these cultures (Figure 11B and C).

655 656

Figure 10: Dehydrogenase activity (A) and cell number (B) of MRC-5 fibroblasts grown on

657

glass surface or on PTX loaded and unloaded multilayers. Activity is normalized to the

658

activity of cells grown on the PTX unloaded multilayers while glass surface serves as

659

reference for optimal growth conditions.

660 661

Figure 11: Morphology of MRC-5 cells grown for 72h on glass surface and PTX loaded and

662

unloaded multilayers. A confluent cell monolayer is seen when cells are grown on glass (A).

663

Rarefication of the cell layer is obvious in the PTX loaded samples (B) while formation of

664

cell clusters is seen MRC-5 cells were grown on unloaded multilayers (C).

665

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 34 of 58

666

The poor adhesion of cells to the multilayers may be due to TMC (a chitosan derivative).

667

Chitosan membranes were previously shown to require a surface modification to allow good

668

adhesion and proliferation of fibroblasts

669

chitosan to lower extent than other cell types

670

adhesion and proliferation of fibroblasts as well 77. For example, it was previously found that

671

alginate can dissolve in the growth media through cation exchange (Na+ from the growth

672

media for the Ca2+ from the material), leading to extensive material transformation, even

673

degradation 78. Considering the fact that cells need a stable environment to be attached

674

these results are not that surprising

675

than the cell-growth substrate interaction is the formation of cell clusters. Such clusters were

676

also observed when MRC-5 fibroblasts were seeded on the multilayers (Figure 11C).

75

. It was also found that fibroblasts adhered to 76

. Alginate has to be modified to improve

79-81

,

82

. One indication that cell-cell interactions are stronger

677 678

3.3.3 Biocompatibility on human skin-derived cell culture

679

Considering the above-mentioned results, we chose to perform another safety related testing

680

on human skin derived fibroblasts. Based on the poor adhesion results, there were two main

681

objectives behind our choice of this experimental setup. First, we wanted to assess if the

682

proposed thin film compositions release any toxic degradation products that could negatively

683

influence the cell growth, as well as to evaluate possible local PTX overdoses that could also

684

potentially harm the growing fibroblast cells (especially considering the versatile PTX

685

pharmacodynamic activities). The second objective was to assess the viability of the

686

fibroblasts cell culture from another perspective. For this purpose and in order to obtain as

687

much information as possible with regard to the possible influence of our materials on the

688

fibroblast cells during their targeted application in wound treatment, the actual physiological

689

situation during a potential use of such materials was simulated. This was done through the

690

use of respectively withdrawn samples during the in vitro drug release testing after desired

ACS Paragon Plus Environment

Page 35 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

691

time intervals (e.g. 1, 5, 10, … minutes), composed of the released PTX amount and possible

692

film degradation products (composed of TMC and ALG), for incubation with fibroblasts for

693

24h. The withdrawn samples during the in vitro drug release testing were pipetted together

694

with the fixed number of cells into plastic containers and incubated until confluence was

695

reached. In order to assess the actual influence of the materials we have developed, control

696

samples (ADMEM + 5 wt.% FBS) were prepared, using only the growth media and cells. The

697

results are shown in Figure 12Error! Reference source not found., where each column

698

represents the viability of fibroblasts after incubation for 24h with consecutively withdrawn

699

samples during the release results (therefore the sample names below the columns in

700

minutes).

701 702 703

Figure 12: Biocompatibility testing results based on incubation of fibroblasts for 24h with

704

consecutively withdrawn samples during in vitro release testing (on the x-axis the minutes

705

represent the times, at which the samples were withdrawn during the release study).

706

From Figure 12Error! Reference source not found. we can immediately observe that the

707

samples with the variable PTX content in most cases outperform the control sample. In other

708

words, regardless of the PTX concentrations, release after different time intervals, all samples

709

exhibit at least the same viability as the control sample.

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

710

This result is important in two regards. Firstly, the as-prepared samples are biocompatible

711

regardless of the used PTX concentration, and do not release any harmful TMC or ALG

712

degradation products that could occur during the same period of time. And secondly, the

713

obtained results seem very promising for the best performing material-drug combinations

714

(especially for the samples 3TMC-3ALG-2PTX_10 and 15) with regard to our desire to

715

prepare novel wound dressings that are not only safe, but show even some activity towards

716

healing promotion. Together with the beneficial activity of PTX in lowering the inflammation

717

locally, these could be a much-desired improvement in local treatment of chronic wounds (in

718

our case the chronic venous ulceration). While the samples with the lower incorporated PTX

719

doses (1 and 5 mg/mL respectively) seem to perform as well, the results for the sample with

720

the highest PTX incorporated mount shows a slightly decreased viability, when compared to

721

the control sample. Although there were still no observable dead cells during testing, this

722

concentration might be over the threshold to induce a positive, healing promoting effect, and

723

should therefore be not exceeded, if practical implementation will follow in the future. Trying

724

to understand the positive influence of PTX on the fibroblast growth, we have to take into

725

account that PTX acts as a competitive nonselective phosphodiesterase inhibitor, which raises

726

intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces

727

inflammation and innate immunity

728

also shown before that PTX for itself can contribute to an improved wound healing, especially

729

in treating diabetic ulcers 14.

730

Since this experiment showed that the actual released amounts of the drug and/or degradation

731

products, does not cause a harmful effect on the fibroblasts, we are positive that the overall

732

performance of the prepared multilayers is still very much beneficial.

13, 83

. The latter activity is further assessed below. It was

733 734

3.3.4 Effect on LPS-induced inflammation of monocytes

ACS Paragon Plus Environment

Page 36 of 58

Page 37 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

735

PTX was incorporated into the prepared multilayers mainly due to its versatile

736

pharmacodynamic activities, contributing to an anti-inflammatory effect. To show that the

737

released PTX amounts from the prepared samples can actually lower an inflammatory

738

response, we performed an additional cell based assay using human monocytes and their

739

TNF-α secretion upon stimulation by LPS.

740

We have found that the PTX released from the multilayers was able to suppress secretion of

741

TNF-α induced by endotoxin/lipopolysaccharide (LPS, Figure 13). This effect was

742

significant up to a dilution of 1:10 of the eluates. Eluates produced from the non-loaded

743

samples reduced the LPS-induced cytokine secretion to a much lower extent. Eluates in the

744

absence of LPS stimulation caused no effect on secretion of TNF-α.

745 746

Figure 13: Secretion of TNF-α after exposure to LPS in the presence of PTX loaded samples

747

(LEFT) and PTX only (RIGHT).

748 749

The anti-inflammatory effect of the PTX loaded multilayers could be shown but also eluates

750

from the PTX unloaded samples reduced the LPS-induced secretion of TNF-α. This effect is

751

most probably due to the anti-inflammatory effect of the chitosan derivative TMC and

752

alginate. Nanoparticle formulations containing these two polysaccharides were previously

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

753

shown to exhibit prominent anti-inflammatory effects in monocytes and keratinocytes

754

exposed to Propionibacterium acnes 84.

755 756

3.3.5 Evaluation of the samples possible clinical applicability

757

Let us now once more consider the combined results from the cell based assay in regard of a

758

possible clinical applicability of the PTX loaded multilayers. As written above, the described

759

results prove that there are no local overdoses, which is the more important for a drug like

760

PTX with its various activities that could even locally, in higher doses, possibly inflict

761

unwanted effects. These are still possible, but based on the obtained results, there should not

762

be any serious unwanted effect also on other cells, and hence tissues, with which our

763

formulation could come into contact. Although, the adhesion testing was not that promising,

764

we believe that the other rather positive results, including the proof of the inflammation

765

lowering effect in the released doses, outweight this part.

766

Therefore, we can say that we have prepared formulations with variable PTX content, which

767

exhibit a dual positive pharmacotherapeutic effect. Namely PTX acts by lowering the

768

inflammation locally while the complete samples add to the overall wound healing

769

performance.

770 771 772

4

773

We have prepared a model and “real” multi-layered wound dressing system, composed from

774

two biocompatible polysaccharides and a potent anti-inflammatory drug. The combination of

775

physic-chemical and functional methods, as well as several cell assays, has shown the

776

potential of the mentioned to be used in future treatment of chronic wounds. Since the used

777

drug pentoxifylline was already proven efficient for systemic treatment of the chronic venous

CONCLUSIONS

ACS Paragon Plus Environment

Page 38 of 58

Page 39 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

778

ulceration, we have reason to believe that the prepared wound dressings could significantly

779

improve the treatment of the latter by local controlled delivery of the drug and an overall

780

healing promotion. This was confirmed using viability and immune response related studies

781

in vitro on human skin fibroblasts and monocytes, respectively.

782

The developed preparation procedure allows for a tailorable treatment by the adjustment of

783

the initial incorporated pentoxifylline dose, as well as “cutting” of the multi-layered dressing

784

to the desired wound size. An even easier on-site handling would be possible with the

785

production of the developed wound dressings in the form of a pentoxifylline impregnated

786

role, which the handling clinician just cuts to the appropriate size on site to suit the specific

787

patient needs.

788 789

5

790

This work has been partially financed by the Slovenian National Agency (grant numbers: P3-

791

0036, I0-0029 and P2-0118). The authors are grateful to Dr. D. Reishofer, from the

792

Technical University of Graz/Austria for his help in regard of profilometry measurements.

ACKNOWLEDGEMENT

793 794

6

795

The

CONFLICT OF INTEREST authors

state

no

conflict

ACS Paragon Plus Environment

of

interest.

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

7

REFERENCES

1. Velnar, T.; Bailey, T.; Smrkolj, V., The wound healing process: an overview of the cellular and molecular mechanisms. The Journal of international medical research 2009, 37, (5), 1528-42. 2. Brolmann, F. E.; Ubbink, D. T.; Nelson, E. A.; Munte, K.; van der Horst, C. M.; Vermeulen, H., Evidence-based decisions for local and systemic wound care. Br J Surg 2012, 99, (9), 1172-83. 3. Kujath, P.; Michelsen, A., Wounds - from physiology to wound dressing. Dtsch Arztebl Int 2008, 105, (13), 239-48. 4. Ruckley, C. V., Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997, 48, (1), 67-9. 5. Leu, A. J.; Leu, H. J.; Franzeck, U. K.; Bollinger, A., Microvascular changes in chronic venous insufficiency--a review. Cardiovasc Surg 1995, 3, (3), 237-45. 6. Shields, D. A.; Andaz, S. K.; Sarin, S.; Scurr, J. H.; Coleridge Smith, P. D., Plasma elastase in venous disease. Br J Surg 1994, 81, (10), 1496-9. 7. Pascarella, L.; Schonbein, G. W.; Bergan, J. J., Microcirculation and venous ulcers: a review. Ann Vasc Surg 2005, 19, (6), 921-7. 8. Barrientos, S.; Brem, H.; Stojadinovic, O.; Tomic-Canic, M., Clinical application of growth factors and cytokines in wound healing. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2014, 22, (5), 569-78. 9. Barrientos, S.; Stojadinovic, O.; Golinko, M. S.; Brem, H.; Tomic-Canic, M., Growth factors and cytokines in wound healing. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2008, 16, (5), 585601. 10. Weinstein, D. A.; Kirsner, R. S., Refractory ulcers: the role of tumor necrosis factoralpha. Journal of the American Academy of Dermatology 2010, 63, (1), 146-54. 11. Ashcroft, G. S.; Jeong, M. J.; Ashworth, J. J.; Hardman, M.; Jin, W.; Moutsopoulos, N.; Wild, T.; McCartney-Francis, N.; Sim, D.; McGrady, G.; Song, X. Y.; Wahl, S. M., Tumor necrosis factor-alpha (TNF-alpha) is a therapeutic target for impaired cutaneous wound healing. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2012, 20, (1), 38-49. 12. Sbardella, D.; Fasciglione, G. F.; Gioia, M.; Ciaccio, C.; Tundo, G. R.; Marini, S.; Coletta, M., Human matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes. Molecular aspects of medicine 2012, 33, (2), 119-208. 13. Jull, A. B.; Arroll, B.; Parag, V.; Waters, J., Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 2012, 12, CD001733. 14. Jull, A.; Waters, J.; Arroll, B., Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet 2002, 359, (9317), 1550-4. 15. Magnusson, M.; Gunnarsson, M.; Berntorp, E.; Bjorkman, S.; Hoglund, P., Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans. Eur J Pharmacol 2008, 581, (3), 290-5. 16. Windmeier, C.; Gressner, A. M., Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. General pharmacology 1997, 29, (2), 181-96. 17. Strieter, R. M.; Remick, D. G.; Ward, P. A.; Spengler, R. N.; Lynch, J. P., 3rd; Larrick, J.; Kunkel, S. L., Cellular and molecular regulation of tumor necrosis factor-alpha

ACS Paragon Plus Environment

Page 40 of 58

Page 41 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

production by pentoxifylline. Biochemical and biophysical research communications 1988, 155, (3), 1230-6. 18. Reed, W. R.; DeGowin, R. L., Suppressive effects of pentoxifylline on natural killer cell activity. The Journal of laboratory and clinical medicine 1992, 119, (6), 763-71. 19. Elsner, J. J.; Zilberman, M., Antibiotic-eluting bioresorbable composite fibers for wound healing applications: microstructure, drug delivery and mechanical properties. Acta Biomater 2009, 5, (8), 2872-83. 20. Mogoşanu, G. D.; Grumezescu, A. M., Natural and synthetic polymers for wounds and burns dressing. Int J Pharmaceut 2014, 463, (2), 127-136. 21. Mayet, N.; Choonara, Y. E.; Kumar, P.; Tomar, L. K.; Tyagi, C.; Du Toit, L. C.; Pillay, V., A Comprehensive Review of Advanced Biopolymeric Wound Healing Systems. J Pharm Sci 2014, 103, (8), 2211-2230. 22. Anand, S. C., Implantable Devices: An Overview. In Medical Textiles and Biomaterials for Healthcare, Woodhead Publishing: 2006; pp 329-334. 23. Skórkowska-Telichowska, K.; Czemplik, M.; Kulma, A.; Szopa, J., The local treatment and available dressings designed for chronic wounds. Journal of the American Academy of Dermatology 2013, 68, (4), e117-e126. 24. Stana, J.; Stropnik, D.; Jevsek, M.; Strnad, S., Studija krvne skladnosti modificiranih sinteticnih polimernih povrsin za vsadke : raziskovalna naloga. Univerza, Medicinska fakulteta: Maribor, 2008. 25. Hagenaars, N.; Verheul, R. J.; Mooren, I.; de Jong, P. H. J. L. F.; Mastrobattista, E.; Glansbeek, H. L.; Heldens, J. G. M.; van den Bosch, H.; Hennink, W. E.; Jiskoot, W., Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release 2009, 140, (2), 126-133. 26. Doyle, J. W.; Roth, T. P.; Smith, R. M.; Li, Y.-Q.; Dunn, R. M., Effect of calcium alginate on cellular wound healing processes modeled in vitro. Journal of Biomedical Materials Research 1996, 32, (4), 561-568. 27. Li, X. L.; Han, G. T.; Zhang, Y. M.; Jiang, W.; Xia, Y. Z., Preparation and Physical Properties of Cavernous Calcium Alginate Wound Dressings. Advanced Textile Materials, Pts 1-3 2011, 332-334, 1670-1675. 28. Limova, M., Evaluation of two calcium alginate dressings in the management of venous ulcers. Ostomy Wound Manage 2003, 49, (9), 26-33. 29. Peršin, Z.; Maver, U.; Pivec, T.; Maver, T.; Vesel, A.; Mozetič, M.; Stana-Kleinschek, K., Novel cellulose based materials for safe and efficient wound treatment. Carbohyd Polym 2014, 100, 55-64. 30. Maver, T.; Maver, U.; Mostegel, F.; Grieser, T.; Spirk, S.; Smrke, D.; Stana Kleinschek, K., Cellulose based thin films as a platform for drug release studies to mimick wound dressing materials. Cellulose 2015, 22, 749-761. 31. Maver, T.; Kurečič, M.; Smrke, D. M.; Kleinschek, K. S.; Maver, U., Electrospun nanofibrous CMC/PEO as a part of an effective pain-relieving wound dressing. J Sol-Gel Sci Techn 2015, 1-12. 32. Richardson, J. J.; Bjornmalm, M.; Caruso, F., Multilayer assembly. Technologydriven layer-by-layer assembly of nanofilms. Science 2015, 348, (6233), aaa2491. 33. Borges, J.; Mano, J. F., Molecular Interactions Driving the Layer-by-Layer Assembly of Multilayers. Chemical Reviews 2014, 114, (18), 8883-8942. 34. Zelikin, A. N., Drug Releasing Polymer Thin Films: New Era of Surface-Mediated Drug Delivery. Acs Nano 2010, 4, (5), 2494-2509. 35. Jiang, B.; Barnett, J. B.; Li, B., Advances in polyelectrolyte multilayer nanofilms as tunable drug delivery systems. Nanotechnology, science and applications 2009, 2, 21.

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

36. Ariga, K.; McShane, M.; Lvov, Y. M.; Ji, Q.; Hill, J. P., Layer-by-layer assembly for drug delivery and related applications. Expert Opin Drug Deliv 2011, 8, (5), 633-44. 37. Redolfi Riva, E.; Desii, A.; Sartini, S.; La Motta, C.; Mazzolai, B.; Mattoli, V., PMMA/Polysaccharides Nanofilm Loaded with Adenosine Deaminase Inhibitor for Targeted Anti-inflammatory Drug Delivery. Langmuir 2013, 29, (43), 13190-13197. 38. Silva, D.; Pinto, L. F.; Bozukova, D.; Santos, L. F.; Serro, A. P.; Saramago, B., Chitosan/alginate based multilayers to control drug release from ophthalmic lens. Colloids and surfaces. B, Biointerfaces 2016, 147, 81-9. 39. Vannozzi, L.; Ricotti, L.; Filippeschi, C.; Sartini, S.; Coviello, V.; Piazza, V.; Pingue, P.; La Motta, C.; Dario, P.; Menciassi, A., Nanostructured ultra-thin patches for ultrasoundmodulated delivery of anti-restenotic drug. Int J Nanomed 2016, 11, 69-92. 40. Marx, K. A., Quartz Crystal Microbalance:  A Useful Tool for Studying Thin Polymer Films and Complex Biomolecular Systems at the Solution−Surface Interface. Biomacromolecules 2003, 4, (5), 1099-1120. 41. Maver, U.; Godec, A.; Bele, M.; Planinšek, O.; Gaberšček, M.; Srčič, S.; Jamnik, J., Novel hybrid silica xerogels for stabilization and controlled release of drug. Int J Pharmaceut 2007, 330, (1-2), 164-174. 42. Taatjes, D. J.; Mossman, B. T., Cell imaging techniques : methods and protocols. Humana Press: Totowa, N.J., 2006; p xiv, 490 p. 43. Bracic, M.; Mohan, T.; Kargl, R.; Griesser, T.; Hribernik, S.; Kostler, S.; StanaKleinschek, K.; Fras-Zemljic, L., Preparation of PDMS ultrathin films and patterned surface modification with cellulose. RSC Advances 2014, 4, (23), 11955-11961. 44. Mohan, T.; Niegelhell, K.; Nagaraj, C.; Reishofer, D.; Spirk, S.; Olschewski, A.; Stana Kleinschek, K.; Kargl, R., Interaction of Tissue Engineering Substrates with Serum Proteins and Its Influence on Human Primary Endothelial Cells. Biomacromolecules 2017, 18, (2), 413-421. 45. Mohan, T.; Findenig, G.; Höllbacher, S.; Cerny, C.; Ristić, T.; Kargl, R.; Spirk, S.; Maver, U.; Stana-Kleinschek, K.; Ribitsch, V., Interaction and enrichment of protein on cationic polysaccharide surfaces. Colloids and Surfaces B: Biointerfaces 2014, 123, 533-541. 46. Ramalingam, P.; Ko, Y. T., Enhanced Oral Delivery of Curcumin from N-trimethyl Chitosan Surface-Modified Solid Lipid Nanoparticles: Pharmacokinetic and Brain Distribution Evaluations. Pharmaceut Res 2015, 32, (2), 389-402. 47. Kim, Y.; Kim, G., Collagen/alginate scaffolds comprising core (PCL)-shell (collagen/alginate) struts for hard tissue regeneration: fabrication, characterisation, and cellular activities. Journal of Materials Chemistry B 2013, 1, (25), 3185-3194. 48. Rahim, S. A.; Carter, P. A.; Elkordy, A. A., Design and evaluation of effervescent floating tablets based on hydroxyethyl cellulose and sodium alginate using pentoxifylline as a model drug. Drug design, development and therapy 2015, 9, 1843-1857. 49. Frykberg, R. G.; Banks, J., Challenges in the Treatment of Chronic Wounds. Advances in wound care 2015, 4, (9), 560-582. 50. Tricco, A. C.; Antony, J.; Vafaei, A.; Khan, P. A.; Harrington, A.; Cogo, E.; Wilson, C.; Perrier, L.; Hui, W.; Straus, S. E., Seeking effective interventions to treat complex wounds: an overview of systematic reviews. BMC medicine 2015, 13, 89. 51. Maver, T.; Hribernik, S.; Mohan, T.; Smrke, D. M.; Maver, U.; Stana-Kleinschek, K., Functional wound dressing materials with highly tunable drug release properties. RSC Advances 2015, 5, (95), 77873-77884. 52. Boateng, J. S.; Matthews, K. H.; Stevens, H. N. E.; Eccleston, G. M., Wound healing dressings and drug delivery systems: A review. J Pharm Sci 2008, 97, (8), 2892-2923.

ACS Paragon Plus Environment

Page 42 of 58

Page 43 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

53. Powers, J. G.; Higham, C.; Broussard, K.; Phillips, T. J., Wound healing and treating wounds: Chronic wound care and management. Journal of the American Academy of Dermatology 2016, 74, (4), 607-25. 54. Delfour, M. C., Drug Release Kinetics from Biodegradable Polymers via Partial Differential Equations Models. Acta Appl Math 2012, 118, (1), 161-183. 55. Yin, C.; Li, X. C., Anomalous diffusion of drug release from a slab matrix: Fractional diffusion models. Int J Pharm 2011, 418, (1), 78-87. 56. Aguzzi, C.; Cerezo, P.; Salcedo, I.; Sanchez, R.; Viseras, C., Mathematical models describing drug release from biopolymeric delivery systems. Mater Technol 2010, 25, (3-4), 205-211. 57. Maver, U.; Bele, M.; Jamnik, J.; Gaberšček, M.; Planinšek, O., A fast and simple method for preparation of calcium carbonate-drug composites for fast drug release. Mater Res Bull 2013, 48, (1), 137-145. 58. Nadrah, P.; Maver, U.; Jemec, A.; Tišler, T.; Bele, M.; Dražić, G.; Benčina, M.; Pintar, A.; Planinšek, O.; Gaberšček, M., Hindered Disulfide Bonds to Regulate Release Rate of Model Drug from Mesoporous Silica. ACS Appl. Mater. Interfaces 2013, 5, (9), 3908-3915. 59. Žužek Rožman, K.; Pečko, D.; Šturm, S.; Maver, U.; Nadrah, P.; Bele, M.; Kobe, S., Electrochemical synthesis and characterization of Fe 70Pd 30 nanotubes for drug-delivery applications. Mater Chem Phys 2012, 133, (1), 218-224. 60. Ukmar, T.; Maver, U.; Planinšek, O.; Pintar, A.; Kaučič, V.; Godec, A.; Gaberšček, M., Guest-host van der Waals interactions decisively affect the molecular transport in mesoporous media. J Mater Chem 2012, 22, (3), 1112-1120. 61. Ukmar, T.; Maver, U.; Planinšek, O.; Kaučič, V.; Gaberšček, M.; Godec, A., Understanding controlled drug release from mesoporous silicates: Theory and experiment. J Control Release 2011, 155, (3), 409-417. 62. Maver, T.; Maver, U.; Mostegel, F.; Griesser, T.; Spirk, S.; Smrke, D.; StanaKleinschek, K., Cellulose based thin films as a platform for drug release studies to mimick wound dressing materials. Cellulose 2015, 22, (1), 749-761. 63. Korsmeyer, R. W.; Gurny, R.; Doelker, E.; Buri, P.; Peppas, N. A., Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci 1983, 72, (10), 1189-91. 64. Peppas, N. A., A model of dissolution-controlled solute release from porous drug delivery polymeric systems. J Biomed Mater Res 1983, 17, (6), 1079-87. 65. Vanbommel, E. M. G.; Dezentje, R. F. R.; Crommelin, D. J. A.; Fokkens, J. G., Drug Release Kinetics from the Gradient Matrix System - Mathematical-Modeling. Int J Pharmaceut 1991, 72, (1), 19-27. 66. Ubbink, D. T.; Santema, T. B.; Stoekenbroek, R. M., Systemic wound care: a metareview of cochrane systematic reviews. Surgical technology international 2014, 24, 99-111. 67. Uklejewski, R.; Rogala, P.; Winiecki, M.; Kedzia, A.; Ruszkowski, P., Preliminary Results of Implantation in Animal Model and Osteoblast Culture Evaluation of Prototypes of Biomimetic Multispiked Connecting Scaffold for Noncemented Stemless Resurfacing Hip Arthroplasty Endoprostheses. Biomed Res Int, doi: 10.1155/2013/689089 2013. 68. Santillan, G.; Morelli, S.; Katz, S.; Mondelo, N.; Boland, R.; Puche, R.; Roldan, E., Action of the novel bisphosphonate lidadronate in animal models and osteoblast-like cells. Bone 2004, 34, S69-S70. 69. Ma, R.; Tang, S.; Tan, H.; Lin, W.; Wang, Y.; Wei, J.; Zhao, L.; Tang, T., Preparation, characterization, and in vitro osteoblast functions of a nanohydroxyapatite/polyetheretherketone biocomposite as orthopedic implant material. Int J Nanomedicine 2014, 9, 3949-61.

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

70. Gyorgyey, A.; Ungvari, K.; Kecskemeti, G.; Kopniczky, J.; Hopp, B.; Oszko, A.; Pelsoczi, I.; Rakonczay, Z.; Nagy, K.; Turzo, K., Attachment and proliferation of human osteoblast-like cells (MG-63) on laser-ablated titanium implant material. Materials science & engineering. C, Materials for biological applications 2013, 33, (7), 4251-9. 71. Czekanska, E. M.; Stoddart, M. J.; Ralphs, J. R.; Richards, R. G.; Hayes, J. S., A phenotypic comparison of osteoblast cell lines versus human primary osteoblasts for biomaterials testing. J Biomed Mater Res A 2014, 102, (8), 2636-43. 72. Feyli, S. A.; Ghanbari, A.; Keshtmand, Z., Therapeutic effect of pentoxifylline on reproductive parameters in diabetic male mice. Andrologia 2017, 49, (1). 73. Massart, J.; Robin, M. A.; Noury, F.; Fautrel, A.; Letteron, P.; Bado, A.; Eliat, P. A.; Fromenty, B., Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. British journal of pharmacology 2012, 165, (5), 1361-74. 74. Teicher, B.; Holden, S.; Herman, T.; Epelbaum, R.; Pardee, A.; Dezube, B., Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer research 1991, 11, (4), 1555-1560. 75. Luna, S. M.; Silva, S. S.; Gomes, M. E.; Mano, J. F.; Reis, R. L., Cell adhesion and proliferation onto chitosan-based membranes treated by plasma surface modification. J Biomater Appl 2011, 26, (1), 101-16. 76. Carvalho, C. R.; Lopez-Cebral, R.; Silva-Correia, J.; Silva, J. M.; Mano, J. F.; Silva, T. H.; Freier, T.; Reis, R. L.; Oliveira, J. M., Investigation of cell adhesion in chitosan membranes for peripheral nerve regeneration. Materials science & engineering. C, Materials for biological applications 2017, 71, 1122-1134. 77. Sarker, B.; Singh, R.; Silva, R.; Roether, J. A.; Kaschta, J.; Detsch, R.; Schubert, D. W.; Cicha, I.; Boccaccini, A. R., Evaluation of fibroblasts adhesion and proliferation on alginate-gelatin crosslinked hydrogel. PloS one 2014, 9, (9), e107952. 78. Maver, T.; Gradišnik, L.; Kurečič, M.; Hribernik, S.; Smrke, D. M.; Maver, U.; Kleinschek, K. S., Layering of different materials to achieve optimal conditions for treatment of painful wounds. Int J Pharmaceut 2017, 529, (1–2), 576-588. 79. Hersel, U.; Dahmen, C.; Kessler, H., RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24, (24), 4385-4415. 80. Puppi, D.; Chiellini, F.; Piras, A.; Chiellini, E., Polymeric materials for bone and cartilage repair. Progress in Polymer Science 2010, 35, (4), 403-440. 81. Shin, H.; Jo, S.; Mikos, A. G., Biomimetic materials for tissue engineering. Biomaterials 2003, 24, (24), 4353-4364. 82. Lee, K. Y.; Mooney, D. J., Alginate: properties and biomedical applications. Prog Polym Sci 2012, 37, (1), 106-126. 83. Babaei, S.; Bayat, M.; Nouruzian, M.; Bayat, M., Pentoxifylline improves cutaneous wound healing in streptozotocin-induced diabetic rats. European Journal of Pharmacology 2013, 700, (1–3), 165-172. 84. Friedman, A. J.; Phan, J.; Schairer, D. O.; Champer, J.; Qin, M.; Pirouz, A.; BlecherPaz, K.; Oren, A.; Liu, P. T.; Modlin, R. L.; Kim, J., Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens. J Invest Dermatol 2013, 133, (5), 1231-9.

ACS Paragon Plus Environment

Page 44 of 58

Page 45 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Table of contetns graphic

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 1: Schematic depiction of the prepared multi-layered films. 186x152mm (300 x 300 DPI)

ACS Paragon Plus Environment

Page 46 of 58

Page 47 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 2: Layer thickness and roughness (a), and QCM-D dry mass (b) of multilayer polysaccharide nanofilms assembled from the oppositely charged TMC and ALG. 379x266mm (300 x 300 DPI)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 3: Water contact angle of multilayer polysaccharide nanofilms assembled from the oppositely charged TMC and ALG. 290x474mm (300 x 300 DPI)

ACS Paragon Plus Environment

Page 48 of 58

Page 49 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 4: ATR-IR spectra of multilayer polysaccharide nanofilms prepared (a) without and (b) with PTX incorporation at different concentrations. The spectra of multilayers built on alginate dressing and pure PTX drug is shown in (b). 293x499mm (300 x 300 DPI)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 5: AFM height images of multilayer polysaccharide nanofilms, incorporated with PTX at different concentrations. Top: 1 x 1 cm2 and bottom: 5 x 5 cm2. 55x17mm (300 x 300 DPI)

ACS Paragon Plus Environment

Page 50 of 58

Page 51 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 6: Results from the in vitro release study: a) PTX mass as a function of time, b) linearity testing of the dependence between the drug loading and released PTX mass, c) the % of release PTX as a function of time, d) first derivatives of the release data for all samples, e) fitting of the release profiles up to 360 min using the Zero order model, and f) fitting of the release data from 360 min to 8640 min using the Korsmayer-Peppas model. 208x236mm (300 x 300 DPI)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 7: Schematic depiction of the influence of the final multilayer preparation step on PTX distribution in the sample. Black arrows show the presumable burst like release, whereas the red arrows present the slower release after 360 min. 318x113mm (150 x 150 DPI)

ACS Paragon Plus Environment

Page 52 of 58

Page 53 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 8: Morphology of MRC-5 cells exposed to undiluted eluates of PTX loaded (A) and unloaded samples (B) for 48h compared to untreated cells (C). 35x6mm (300 x 300 DPI)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 9: Dehydrogenase activity as indication for cell viability of MRC-5 cells exposed to undiluted (pure) and diluted eluates of PTX loaded (LEFT) and unloaded samples (RIGTH) at time points 24h, 48h, and 72h. Activity is normalized to untreated cells as 100% 168x95mm (150 x 150 DPI)

ACS Paragon Plus Environment

Page 54 of 58

Page 55 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 10: Dehydrogenase activity (A) and cell number (B) of MRC-5 fibroblasts grown on glass surface or on PTX loaded and unloaded multilayers. Activity is normalized to the activity of cells grown on the PTX unloaded multilayers while glass surface serves as reference for optimal growth conditions. 58x17mm (300 x 300 DPI)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 11: Morphology of MRC-5 cells grown for 72h on glass surface and PTX loaded and unloaded multilayers. A confluent cell monolayer is seen when cells are grown on glass (A). Rarefication of the cell layer is obvious in the PTX loaded samples (B) while formation of cell clusters is seen MRC-5 cells were grown on unloaded multilayers (C). 36x6mm (300 x 300 DPI)

ACS Paragon Plus Environment

Page 56 of 58

Page 57 of 58

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Figure 12: Biocompatibility testing results based on incubation of fibroblasts for 24h with consecutively withdrawn samples during in vitro release testing (on the x-axis the minutes represent the times, at which the samples were withdrawn during the release study). 297x119mm (150 x 150 DPI)

ACS Paragon Plus Environment

Biomacromolecules

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Figure 13: Secretion of TNF-α after exposure to LPS in the presence of PTX loaded samples (LEFT) and PTX only (RIGHT). 327x129mm (150 x 150 DPI)

ACS Paragon Plus Environment

Page 58 of 58